| Company/Division name | Merck |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 500 |
| Year reshoring announced: | 2025 |
| Year reshoring implemented or to be implemented: | 2028 |
| Capital investment ($): | 1000 |
| $/year of sales of reshored product or service: | 29,500,000,000 |
| Country(ies) from which reshored: | Ireland,Singapore |
| City reshored to: | Wilmington |
| State(s) reshored to: | DE |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Keytruda (biomanufacturing), pharmaceuticals |
| What non-domestic negative factors made offshoring less attractive? | Tariffs |
| What domestic positive factors made reshoring more attractive? | Proximity to customers/market |
